Abcellera Biologics Inc (ABCL) Stock Price, Quote & News

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research coll...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 559 9005

Website: www.abcellera.com

Address:

150 West 4th Ave, Vancouver, Canada

SlayQueenOfCalls Jan. 12 at 10:13 PM

$ABCL hi ya’ll! New here. Seems fun!

1 · Reply

Danz_Trades Jan. 12 at 9:26 PM

Great start on a Monday with the team 🫡 I hope you guys killed It Swing positions paid big today $BABA $CRWV $ABCL $GOOG $EOSE New Setups will be posted on X later this evening https://x.com/DanzTrader/status/2010823263211917672?s=20

0 · Reply

Amires Jan. 12 at 8:05 PM

$ABCL History is repeating itself! 🚀 Remember last Jan? JPM 2025 sparked a massive 27% rally and volume exploded past 8.5M shares. 📈 The 2026 setup is even JUICIER: ✅ BREAKING NEWS TODAY: First patients dosed in Phase 2 for ABCL635 (menopause trial)! 🧬 ✅ CASH IN HAND: $36M settlement + future royalties from Bruker secured in Dec. 💰 ✅ MOMENTUM: Volume already hitting 6M+ (up 17% in 2 weeks). Presentation this Wednesday (1/14) @ 3:45 PM PT. Last time we hit that 8M volume mark, the price didn't stop until it touched those $5.25+ levels later in the year. With a clinical-stage pipeline now officially in Phase 2, the sky is the limit. Don't miss the move. Bullish! 🔥 #JPM2026 #Biotech #AbCellera

1 · Reply

TheRealShortSqueezy Jan. 12 at 6:05 PM

$HYFT : Positioned in an $8B+ Global Vaccine Opportunity 💰 MindWalk Holdings Corp. delivered strong growth in its latest quarterly earnings, reinforcing confidence in its Bio-Native AI strategy and adding fuel to growing momentum in the stock. Latest earnings highlights: 🔹 Revenue up 54% YoY to $4.1M, a record quarterly result 🔹 Gross profit up 94%, with margins expanding to ~65% 🔹 Operating loss narrowed, reflecting improving efficiency 🔹 ~$16.5M in cash, supporting continued program advancement These results point to rising demand for MindWalk’s HYFT Deep Data and LensAI platform, alongside disciplined, capital-efficient execution. Backed by recent scientific breakthroughs, $HYFT is gaining visibility and momentum as platform validation continues to resonate with the market. Execution is strengthening, momentum is building, and the setup ahead looks compelling. 📈 Communicated Disclaimer: https://bit.ly/45yIR8a Sector Peers: $CRSP $ABCL $CABA $ENTX

0 · Reply

Stocktradesmoon Jan. 12 at 5:10 PM

$ABCL $ABCL (Jan 12, 2026-daily chart) Every time the red ribbon (mid-term uptrend) has appeared (in Panel 1), it has lasted 1.5 to 2 months. Will history repeat itself this time?

0 · Reply

DianeByard363 Jan. 12 at 5:00 PM

$ABCL popped 6% overnight 😤 I’m putting together a deep dive for anyone new to AbCellera—aiming to break down why this company is so unique and what makes it special. Plan is to have it ready tomorrow (if my schedule allows). Anything specific you want me to cover or clarify? Drop your questions! $BDSX $EOSE Free sharing and subscription @DianeByard363

3 · Reply

Stocktradesmoon Jan. 12 at 4:48 PM

$ABCL Designing ABCL635 like Phase 2 all makes sense now 😎 Another interesting thing is that the administration did mention the potential to fast-track non-hormonal therapy drug for women. Again, could be a stretch, but the accelerated timeline feels promising

0 · Reply

UncleTomFlorida Jan. 12 at 4:46 PM

$ABCL

0 · Reply

UncleTomFlorida Jan. 12 at 4:38 PM

$ABCL

0 · Reply

tranq19 Jan. 12 at 4:22 PM

$ABCL could be a big week, surprised we’re not up big today, but let’s see what happens this afternoon

0 · Reply

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Dec 18, 2025, 9:00 AM EST - 25 days ago

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025, 4:05 PM EST - 5 weeks ago

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

Dec 8, 2025, 1:37 PM EST - 5 weeks ago

AbCellera Biologics Inc. (ABCL) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Nov 22, 2025, 12:23 AM EST - 7 weeks ago

AbCellera Biologics Inc. (ABCL) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 10, 2025, 9:00 AM EST - 2 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 7, 2025, 7:16 PM EST - 2 months ago

AbCellera Biologics Inc. (ABCL) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 2 months ago

AbCellera Reports Q3 2025 Business Results

Oct 7, 2025, 4:05 PM EDT - 3 months ago

AbCellera to Participate at Upcoming Investor Conferences in November and December 2025

Oct 6, 2025, 7:35 AM EDT - 3 months ago

AbCellera Biologics: Entering Growth Phase After A Pause

Sep 29, 2025, 4:05 PM EDT - 3 months ago

AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025

Sep 10, 2025, 9:07 AM EDT - 4 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Aug 27, 2025, 9:00 AM EDT - 4 months ago

AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575

Aug 12, 2025, 4:05 PM EDT - 5 months ago

AbCellera to Participate at Upcoming Investor Conferences in September

Aug 7, 2025, 7:48 PM EDT - 5 months ago

AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 5 months ago

AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

Jul 7, 2025, 4:05 PM EDT - 6 months ago

AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

May 30, 2025, 1:00 PM EDT - 8 months ago

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575

May 14, 2025, 5:00 PM EDT - 8 months ago

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause

May 12, 2025, 3:30 PM EDT - 8 months ago

AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit

May 9, 2025, 7:30 PM EDT - 8 months ago

AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting

May 8, 2025, 10:33 PM EDT - 8 months ago

AbCellera Biologics Inc. (ABCL) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 8 months ago

AbCellera Reports Q1 2025 Business Results

Apr 29, 2025, 3:00 PM EDT - 9 months ago

AbCellera Presents Data Showing Preclinical Efficacy of PSMA x CD3 T-Cell Engagers at AACR 2025

Apr 8, 2025, 4:05 PM EDT - 9 months ago

AbCellera to Participate at Upcoming Investor Conferences in May and June

Apr 3, 2025, 4:05 PM EDT - 10 months ago

AbCellera to Report First Quarter 2025 Financial Results on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 10 months ago

AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

Feb 27, 2025, 11:26 PM EST - 11 months ago

AbCellera Biologics Inc. (ABCL) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 11 months ago

AbCellera Reports Full Year 2024 Business Results

Feb 11, 2025, 4:05 PM EST - 11 months ago

AbCellera to Participate at Upcoming Investor Conferences in March

Jan 21, 2025, 4:05 PM EST - 1 year ago

AbCellera to Report Full Year 2024 Financial Results on February 27, 2025

Jan 13, 2025, 9:00 AM EST - 1 year ago

AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

Dec 23, 2024, 4:39 PM EST - 1 year ago

AbCellera Biologics: Still A Concept Stock

Nov 21, 2024, 4:05 PM EST - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in December and January

Nov 7, 2024, 10:05 AM EST - 1 year ago

AbCellera Presents Data on Applications of T-Cell Engager Platform at SITC 2024

Nov 4, 2024, 7:22 PM EST - 1 year ago

AbCellera Biologics Inc. (ABCL) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results

Oct 22, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in November 2024

Oct 14, 2024, 12:04 PM EDT - 1 year ago

AbCellera: A Platform To Pipeline Transition

Oct 4, 2024, 9:00 AM EDT - 1 year ago

AbCellera Announces Presentation on T-cell Engager Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2024

Sep 26, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Third Quarter 2024 Financial Results on November 4, 2024

Aug 29, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at Upcoming Investor Conferences in September

Aug 23, 2024, 4:43 AM EDT - 1 year ago

AbCellera: A Waiting Game With High Uncertainty

Aug 20, 2024, 9:45 AM EDT - 1 year ago

This Globant Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

GLOB AVDX LRN PGRU

Aug 6, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q2 2024 Business Results

Jul 31, 2024, 9:00 AM EDT - 1 year ago

AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

Jun 25, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Report Second Quarter 2024 Financial Results on August 6, 2024

May 28, 2024, 4:05 PM EDT - 1 year ago

AbCellera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024

May 7, 2024, 11:00 PM EDT - 1 year ago

AbCellera Biologics Inc. (ABCL) Q1 2024 Earnings Call Transcript

May 7, 2024, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2024 Business Results

SlayQueenOfCalls Jan. 12 at 10:13 PM

$ABCL hi ya’ll! New here. Seems fun!

1 · Reply

Danz_Trades Jan. 12 at 9:26 PM

0 · Reply

Amires Jan. 12 at 8:05 PM

1 · Reply

TheRealShortSqueezy Jan. 12 at 6:05 PM

0 · Reply

Stocktradesmoon Jan. 12 at 5:10 PM

$ABCL $ABCL (Jan 12, 2026-daily chart) Every time the red ribbon (mid-term uptrend) has appeared (in Panel 1), it has lasted 1.5 to 2 months. Will history repeat itself this time?

0 · Reply

DianeByard363 Jan. 12 at 5:00 PM

3 · Reply

Stocktradesmoon Jan. 12 at 4:48 PM

0 · Reply

UncleTomFlorida Jan. 12 at 4:46 PM

$ABCL

0 · Reply

UncleTomFlorida Jan. 12 at 4:38 PM

$ABCL

0 · Reply

tranq19 Jan. 12 at 4:22 PM

$ABCL could be a big week, surprised we’re not up big today, but let’s see what happens this afternoon

0 · Reply

Cassek86 Jan. 12 at 3:56 PM

$ABCL We will close green today.

1 · Reply

Stocktradesmoon Jan. 12 at 3:53 PM

$ABCL “Advancing this program into Phase 2 marks an important milestone in our clinical development efforts. Based on encouraging safety and pharmacodynamic data in the Phase 1 dose escalation portion, along with evidence of high target engagement and a strong mechanistic foundation, we are eager to evaluate ABCL635 in a randomized, double-blind Phase 2 study,” said Sarah Noonberg, M.D., Ph.D., Chief Medical Officer of AbCellera.” “AbCellera has recently designated the ABCL635 Phase 1 trial as a Phase 1/2 trial, which includes a randomized Phase 2 Proof-of-Concept study (Part C) in the appropriate patient population. With Phase 2 enrollment underway, the company anticipates top-line clinical results for both phases in Q3 2026.” AbCellera will be presenting at JPM on Wednesday, too. Looking forward to hearing more comments from management . $ABCL

1 · Reply

JennyRowes Jan. 12 at 3:41 PM

$ABCL watched jpm talk from last year. They went from preclinical biotech to phase 2 in less than a year!

0 · Reply

Stocktradesmoon Jan. 12 at 3:20 PM

$ABCL

2 · Reply

DeMampCamp Jan. 12 at 3:19 PM

$ABCL Fantastic news, but totally perplexed as to why it's not moving the stock! This is the type of unexpected news we need to move this stock to area's we haven't seen in 4+ years. https://investors.abcellera.com/news/news-releases/2026/AbCellera-Announces-First-Patients-Dosed-in-Phase-2-Portion-of-its-Phase-12-Clinical-Trial-of-ABCL635-for-the-Treatment-of-Vasomotor-Symptoms-Due-to-Menopause/default.aspx

2 · Reply

Ed_Ng Jan. 12 at 3:18 PM

$ABCL

0 · Reply

Ed_Ng Jan. 12 at 3:11 PM

$ABCL sell the news. I meant "fraud news"!

0 · Reply

_Stapler Jan. 12 at 3:00 PM

$ABCL CEO should be let-go for brining this $6B company to $1B Market Cap. it is not working.

1 · Reply

Stocktradesmoon Jan. 12 at 2:24 PM

$ABCL Abcellera Biologics $ABCL announces that the clinical trial with ABCL635 —indicated for treating menopause symptoms— advances to phase 2 after obtaining positive preliminary results from phase 1. It's very good news

3 · Reply

DeMampCamp Jan. 12 at 2:13 PM

$ABCL Watch for the nasty gap close at the opening bell, careful buying here! There are differences of opinions on gap closes, 1) closing price of the previous day 2) the high of day price of the previous day. I personally use the high of day, so in my opinion, gap at $4.50, but won't be surprised to see them try and really hammer the momentum today with the overall bloodbath market we have on tap! Best of luck to us all, cheers and make it a great Monday!

0 · Reply

TheDrunkTrader69 Jan. 12 at 2:10 PM

$ABCL Been saying it for a long time now, this is a buy and hold stock, buy buy buy right now you wont regret it later.

1 · Reply

Odoji Jan. 12 at 1:40 PM

$ABCL

0 · Reply

Market Cap	1.31B
Revenue (ttm)	28.83M
Net Income (ttm)	-162.86M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-564.90%
Debt to Equity Ratio	0.00

Volume	5,021,646
Avg Vol	4,298,132
Day's Range	N/A - N/A
Shares Out	299.34M
Stochastic %K	88%
Beta	0.73
Analysts	Strong Sell
Price Target	$9.00